2137 Stock Overview
Focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Brii Biosciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.81 |
| 52 Week High | HK$3.09 |
| 52 Week Low | HK$0.80 |
| Beta | 1.51 |
| 1 Month Change | -6.70% |
| 3 Month Change | 61.61% |
| 1 Year Change | 42.52% |
| 3 Year Change | -79.12% |
| 5 Year Change | n/a |
| Change since IPO | -92.11% |
Recent News & Updates
Recent updates
Brii Biosciences (HKG:2137) Is In A Good Position To Deliver On Growth Plans
Nov 19
Here's Why We're Not Too Worried About Brii Biosciences' (HKG:2137) Cash Burn Situation
Jul 26Companies Like Brii Biosciences (HKG:2137) Are In A Position To Invest In Growth
Jan 12We're Hopeful That Brii Biosciences (HKG:2137) Will Use Its Cash Wisely
Sep 20We're Not Worried About Brii Biosciences' (HKG:2137) Cash Burn
Mar 24Shareholder Returns
| 2137 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -5.7% | -1.5% | 3.8% |
| 1Y | 42.5% | 39.9% | 14.6% |
Return vs Industry: 2137 exceeded the Hong Kong Biotechs industry which returned 39.9% over the past year.
Return vs Market: 2137 exceeded the Hong Kong Market which returned 14.6% over the past year.
Price Volatility
| 2137 volatility | |
|---|---|
| 2137 Average Weekly Movement | 20.2% |
| Biotechs Industry Average Movement | 13.7% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in HK Market | 15.5% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 2137's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2137's weekly volatility has increased from 13% to 20% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 98 | Zhi Hong | www.briibio.com |
Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody which are in Phase 2 of the development stage for functional cure of HBV for Hepatitis B; and BRII-732 that has completed Phase 1 clinical trial and BRII-753, which is in preclinical stage for the treatment of HIV. It also develops BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative bacterial infections, which has completed Phase 1; and Epetraborole for oral treatment for patients with chronic NTM lung disease.
Brii Biosciences Limited Fundamentals Summary
| 2137 fundamental statistics | |
|---|---|
| Market cap | HK$1.30b |
| Earnings (TTM) | -HK$550.47m |
| Revenue (TTM) | HK$59.57m |
21.9x
P/S Ratio-2.4x
P/E RatioIs 2137 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2137 income statement (TTM) | |
|---|---|
| Revenue | CN¥54.99m |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥54.99m |
| Other Expenses | CN¥563.15m |
| Earnings | -CN¥508.16m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.71 |
| Gross Margin | 100.00% |
| Net Profit Margin | -924.08% |
| Debt/Equity Ratio | 0.7% |
How did 2137 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/15 20:56 |
| End of Day Share Price | 2025/05/15 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Brii Biosciences Limited is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wangbin Zhou | China International Capital Corporation Limited |
| Xiao Wei Lin | Everbright Securities Co. Ltd. |
| Geoffrey Porges | Leerink Partners LLC |